Precigen’s (PGEN) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Precigen (NASDAQ:PGEN) in a research note released on Thursday,Benzinga reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $4.00. HC Wainwright also issued estimates for Precigen’s FY2026 earnings at ($0.01) EPS, FY2027 earnings at $0.20 EPS and FY2029 earnings at $0.62 EPS.

Separately, JMP Securities reiterated a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat, Precigen has an average rating of “Hold” and a consensus price target of $7.00.

Precigen Stock Up 3.7 %

Shares of NASDAQ PGEN opened at $1.39 on Thursday. The stock has a market capitalization of $407.09 million, a PE ratio of -2.53 and a beta of 1.65. Precigen has a 52-week low of $0.65 and a 52-week high of $1.93. The firm has a fifty day moving average of $0.94 and a 200-day moving average of $1.06.

Institutional Investors Weigh In On Precigen

Institutional investors and hedge funds have recently modified their holdings of the stock. Iridian Asset Management LLC CT increased its stake in Precigen by 82.5% in the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after buying an additional 1,706,815 shares during the period. Geode Capital Management LLC grew its position in Precigen by 4.8% during the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after buying an additional 149,829 shares in the last quarter. State Street Corp increased its holdings in Precigen by 1.0% in the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock valued at $2,720,000 after buying an additional 29,253 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Precigen by 11.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after acquiring an additional 127,467 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Precigen by 12.4% during the second quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock worth $1,869,000 after acquiring an additional 130,500 shares in the last quarter. 33.51% of the stock is owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.